摘要
目的 探讨仑伐替尼联合信迪利单抗一线治疗晚期肝细胞癌(HCC)疗效及安全性.方法 选取2023年1月-2024年1月期间我院收治的26例中晚期肝癌患者作为研究对象,按1∶1分为两组,每组各13例.对照组患者采用口服仑伐替尼+VMAT技术治疗,试验组采用仑伐替尼+信迪利单抗技术治疗.对照组口服仑伐替尼,按常规临床剂量给药(体重≤60kg,每天8mg;>60kg,每天12mg),每日一次,早晨空腹或随餐服用,无法耐受者剂量适当降低.试验组给予患者信迪利单抗200mg第1天,每三周一疗程,仑伐替尼使用方法同对照组.用药前需收集基线资料(血常规、尿常规、甲状腺功能、生化、影像学等),治疗期间监测血压1次/天,每1周复查血常规、生化、尿常规等,2个周期后,复查影像学检查,评价疗效,治疗期间注意观察不良反应.结果 两组患者一般资料相比,差异无统计学意义(P>0.05).两组患者治疗后无CR病例,试验组PR者6例(46%),SD者3例(23%),PD者4例(31%),ORR为46%,DCR为69%;对照组PR者3例(23%),SD者2例(15%),PD者8例(62%),ORR为23%,DCR为38%.试验组ORR、DCR高于对照组,但差异无统计学意义(P>0.05).试验组OS和PFS优于对照组,但差异无统计学意义(P>0.05).两组患者的主要不良反应为高血压、手足综合征、腹泻、食欲下降、血小板减少和发热,均较为轻微且差异无统计学意义(P>0.05).结论 仑伐替尼联合信迪利单抗一线治疗晚期肝细胞癌(HCC)疗效确切,不显著增加患者不良反应.
Objective To explore lenvatinib plus Sintilimabin first-line treatment of advanced HCC.Methods A total of 26 patients with advanced liver cancer admitted to our hospital from January 2023 to January 2024 were selected as the study subjects,and divided into two groups with 13 cases in each group in a 1:1 ratio.The control group patients were treated with oral lenvatinib+VMAT technology,while the experimental group was treated with lenvatinib+Sintilimabin technology.The control group received oral lenvatinib at a conventional clinical dose(body weight≤60kg,8mg per day;>60kg,12mg per day),once daily,on an empty stomach or with meals in the morning.The dose was appropriately reduced for those who were unable to tolerate it.The experimental group received 20Omg of Sintilimabin for the first day,with a course of treatment every three weeks.The use of lenvatinib was the same as that of the control group.Baseline data should be collected before medication.Blood pressure should be monitored once a day during the treatment period,and blood routine,biochemistry,urine routine,etc.should be reviewed every week.After two cycles,imaging examinations should be reviewed to evaluate the efficacy.Adverse reactions should be observed during the treatment period.Results There were no significant in two groups(P>0.05).There were no CR cases after treatment.In experimental group,6 cases of PR(46%),3 cases of SD(23%),4 cases of PD(31%),with an ORR of 46%and a DCR of 69%were observed;in control group,the PR,SD and PD were 23%,15%and 62%,respectively.The ORR and DCR of the experimental group were higher than those of the control group but without significance(P>0.05).The overall survival OS and PFS were also without significance(P>0.05).The main adverse reactions of the two groups of patients were hypertension,hand and foot syndrome,diarrhea,decreased appetite,thrombocytopenia,and fever,both of which were relatively mild and the difference was not statistically significant(P>0.05).Conclusion The first-line treatment of advanced hepatoce
作者
陈国凤
楚杰
张宏伟
Chen Guofeng;Chu Jie;Zhang Hongwei(Ziyang Central Hospital,Ziyang,Sichuan 641399,China)
出处
《首都食品与医药》
2024年第22期70-72,共3页
Capital Food Medicine
基金
四川省抗癌协会2022年肿瘤临床科研项目(齐鲁)课题(编号:XH2022-119)。
